Non-Hodgkin Lymphoma | Tumor

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

June 6th 2021, 5:00pm


Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

FDA Approves Xalkori for Children, Young Adults With Relapsed or Refractory Anaplastic Large Cell Lymphoma

January 14th 2021, 10:49pm


The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.

CAR-T Cell Therapy Product for Relapsed/Refractory Large B-Cell Lymphoma Still Under FDA Review

January 6th 2021, 10:00pm


The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.

Friday Frontline: Black Patients with Cancer at Higher Risk for COVID-19 Infections, Colts Punter Looks to Play Again After Successful Cancer Surgery and More

December 18th 2020, 4:30pm


From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.

FDA Approves Rituxan Biosimilar, Riabni, For Patients with Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Two Blood Vessel Disorders

December 17th 2020, 10:52pm


For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.

Treating Waldenstrom’s Macroglobulinemia

December 17th 2020, 4:00pm


In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.

Long-Term Data of Imbruvica-Rituxan Combo in Waldenstrom’s Macroglobulinemia Demonstrates ‘Major Step Forward’

December 8th 2020, 2:15pm


In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020, 7:30pm


The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Kymriah Safely Treats ALL and NHL in Real-World Setting

December 2nd 2020, 7:00pm


Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.

A Look Back at the Beginnings of CAR-T Cell Therapy

December 2nd 2020, 4:00pm


A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?